Informations

At the highly anticipated 2024 San Antonio Breast Cancer Symposium (SABCS), numerous groundbreaking studies in breast cancer treatment were unveiled. Among them, the Working Group for Gynecological Oncology (WSG) presented long-term survival data from the WSG ADAPT-HR+/HER2- early breast cancer chemotherapy cohort (Abstract No.: GS3-04). This study integrates clinical pathology, genomic testing, and endocrine therapy…

The 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee, hosted by the Chinese Anti-Cancer Association Breast Cancer Professional Committee (CBCS) and the Shanghai Anti-Cancer Association, and organized by the Breast Cancer Professional Committee of the Shanghai Anti-Cancer Association, was held from December 20 to 21, 2024, in…

In the field of immunotherapy for colorectal cancer (CRC), ADAR1, an essential RNA-editing enzyme, has gained significant attention in recent years. At the 2024 ESMO Asia Congress, Dr. Da Kang from Dr. Zhizhong Pan’s team at the Sun Yat-sen University Cancer Center presented their latest findings on ADAR1 expression in T cells and its impact…

Previous Phase II NEOTAX study results demonstrated that neoadjuvant therapy with toripalimab combined with axitinib effectively downstaged inferior vena cava tumor thrombi in some patients with renal cell carcinoma (RCC), significantly improving perioperative outcomes. However, resistance to therapy remains a challenge for some patients, necessitating further investigation. At the 2024 ESMO ASIA Congress, Dr. Liangyou…

Epidermal growth factor receptor (EGFR) gene mutations are the most common oncogenic driver mutations in non-small cell lung cancer (NSCLC) patients in China, with a significantly higher incidence compared to Caucasian populations. At the recent ESMO Asia Congress 2024, Dr. Li Zhang from the Sun Yat-sen University Cancer Center presented results from the Phase II…

Facing the global challenge of breast cancer in women’s health, China is advancing the standardization and quality control of breast cancer diagnosis and treatment with unprecedented determination. At the recent 2024 Straits Breast Cancer Forum and the Annual Meeting of the Breast Disease Branch of the Fujian Medical Association, Oncology Frontier invited Dr. Fei Ma,…

Precision treatment for HER2-positive breast cancer has long been a focal point and challenge in breast cancer research. Recently, the DTP study (Abstract No.: RF1-07), presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), offers new insights into addressing this challenge. This study aims to explore the efficacy and safety of combining durvalumab immunotherapy…

With continuous advancements in immunotherapy research, significant progress has been made in improving survival outcomes for patients with non-small cell lung cancer (NSCLC). Recently, based on the results of the KEYNOTE-671 study, the National Medical Products Administration (NMPA) approved the PD-1 inhibitor pembrolizumab for perioperative treatment in patients with resectable stage II, IIIA, and IIIB…